Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study

References

• American Diabetes AssociationStandards of Medical Care in DiabetesDiabetes Care200831S12S5418165335
   PubMed Web of Science ®Google Scholar
• BakrisGBurgessEWeirMTelmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathyKidney Int200874336436918496508
   PubMed Web of Science ®Google Scholar
• CDC. National Diabetes Fact Sheet. 2007.
   Google Scholar
• DronavalliSDukaIBakrisGThe pathogenesis of diabetic nephropathyNat Clin Pract Endocrinol Metab2008444445218607402
   PubMedGoogle Scholar
• VestraMSallerAFiorettoPRole of mesangial expansion in the pathogenesis of diabetic nephropathyJ Nephrol2001144S51S5711798146
   PubMedGoogle Scholar
• ZiyadehFNWolfGPathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathyCurrent Diabetes Reviews200841394518220694
   PubMedGoogle Scholar
• LanghamRGKellyDCoxAProteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibitionDiabetologia200245111572157612436341
   PubMed Web of Science ®Google Scholar
• ReRNMechanisms of disease: local renin angiotensin aldosterone systems and the pathogenesis and treatment of cardiovascular diseaseNat Clin Pract Cardiovasc Med200411424716265259
   PubMedGoogle Scholar
• HauserACHörlWHAngiotensin II type-1-receptor antagonists from the viewpoint of nephrologyJournal Wien Med Wochenschr20011517–8160164
   PubMedGoogle Scholar
• National Kidney Foundation, KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney DiseaseAm J Kidney Dis2007492 Suppl 2S12S15417276798
   PubMed Web of Science ®Google Scholar
• HoffmannSPodlichDHähnelBAngiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic ratsJ Am Soc Nephrol20041561475148715153558
   PubMed Web of Science ®Google Scholar
• ShibataSNagaseMYoshidaSPodocyte as the target for aldosterone: roles of oxidative stress and Sgk1Hypertension200749235536417200434
   PubMed Web of Science ®Google Scholar
• ParvingHHPerssonFLewisJBAVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathyN Engl J Med2008358232433244618525041
   PubMed Web of Science ®Google Scholar
• CortinovisMCattaneoDPericoNInvestigational drugs for diabetic nephropathyExpert Opin Investig Drugs2008171014871500
   PubMed Web of Science ®Google Scholar
• NistalaRWhaley-ConnellASowersJRRedox control of renal function and hypertensionAntioxid Redox Signal200810122047208918821850
   PubMed Web of Science ®Google Scholar
• RuilopeLJakobsenAHeroysJProspects for renovascular protection by more aggressive renin-angiotensin system controlMedscape J Med200810SupplS518449382
   PubMedGoogle Scholar
• GalleJReduction of proteinuria with angiotensin receptor blockersNat Clin Pract Cardiovasc Med20085 Suppl 1S36S4318580865
   PubMedGoogle Scholar
• ChobanianABakrisGBlackHThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension2003421206125214656957
   PubMed Web of Science ®Google Scholar
• YusufSSleightPPogueJEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med2000342314515310639539
   PubMed Web of Science ®Google Scholar
• RodbyRRohdeRLewisEThe Irbesartan Type II Diabetic Nephropathy TrialNephrol Dial Transplant20001548749710727543
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRCollaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med20013451285186011565517
   PubMed Web of Science ®Google Scholar
• ParvingHLehnertHArnerPIrbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med20013451287087811565519
   PubMed Web of Science ®Google Scholar
• BrennerBCooperMZeeuwDRENAAL Study Investigators. Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL StudyN Engl J Med20013451286186911565518
   PubMed Web of Science ®Google Scholar
• De ZeeuwDRemuzziGParvingHProteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAALKidney Int20046562309232015149345
   PubMed Web of Science ®Google Scholar
• VibertiGWheeldonNMMicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effectCirculation200210667267812163426
   PubMed Web of Science ®Google Scholar
• RuggenentiPFassiAIlievaANephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetesN Engl J Med2004351191941195115516697
   PubMed Web of Science ®Google Scholar
• RemuzziGMaciaMRuggenentiPPrevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT studyJ Am Soc Nephrol2006174 Suppl 2S90S9716565256
   PubMed Web of Science ®Google Scholar
• MannJFSchmiederREMcQueenMRenal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trialLancet2008372963854755318707986
   PubMed Web of Science ®Google Scholar
• BarnettAHBainSCBouterPDiabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathyN Engl J Med2004351191952196115516696
   PubMed Web of Science ®Google Scholar
• SchmiederRDellesCMimranAImpact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetesDiabetes Care2007301351135617337492
   PubMed Web of Science ®Google Scholar
• GalleJSchwedhelmEPinnettiSVIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathyNephrol Dial Transplant200823103174318318450829
   PubMed Web of Science ®Google Scholar
• MakinoHHanedaMBabazonoTThe Telmisartan Renoprotective Study from Incipient Nephropathy to Overt Nephropathy – Rationale, Study Design, Treatment Plan and Baseline Characteristics of the Incipient to Overt: Angiotensin II Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) StudyJ Int Med Res20053367768616372586
   PubMed Web of Science ®Google Scholar
• YusufSTeoKPogueJTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med20083581515475918378520
   PubMed Web of Science ®Google Scholar
• HollenbergNKParvingHHVibertiGAlbuminuria response to very high-dose valsartan in type 2 diabetes mellitusJ Hypertens20072591921192617762658
   PubMed Web of Science ®Google Scholar
• RossingKSchjoedtKJParvingHEnhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuriaKidney Int20056831190119816105050
   PubMed Web of Science ®Google Scholar
• BensonSCPershadsinghHHoCIdentification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activityHypertension200443993100215007034
   PubMed Web of Science ®Google Scholar
• WienenWHauelNVan MeelJPharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277Br J Pharmacol199311012452528220885
   PubMed Web of Science ®Google Scholar
• WolfgangWEntzerothMStangierJA review on telmisartan: a novel, long-acting angiotensin II-receptorCardiovasc Drug Rev2006182127154
   Google Scholar
• KakutaHSudohKSasamataMTelmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockersInt J Clin Pharmacol Re20052514146
   Web of Science ®Google Scholar
• PanchapakesanUPollockCChenXPPAR gamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucoseAm J Physiol Renal Physiol2005289F1153F115815886275
   PubMed Web of Science ®Google Scholar
• GuanYHaoCChaDRThiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorptionNat Med200511886186616007095
   PubMed Web of Science ®Google Scholar
• YangTSoodvilaiSRenal and vascular mechanisms of thiazoli-dinedione-induced fluid retentionPPAR Research2008;943614: doi:10.1155/2008/943614.
   PubMed Web of Science ®Google Scholar
• SchuppMClemenzMGinesteRMolecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activityDiabetes200554123442345216306360
   PubMed Web of Science ®Google Scholar
• ZhangHZhangAKohanDECollecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retentionProc Natl Acad Sci U S A2005102269406941115956187
   PubMed Web of Science ®Google Scholar
• RubenstrunkAHanfRHumDSafety issues and prospects for future generations of PPAR modulatorsBiochim Biophys Acta2007177181065108117428730
   PubMed Web of Science ®Google Scholar
• ZhangFLavanBGregoireFSelective modulators of PPAR-γ activity: molecular aspects related to obesity and side-effectsPPAR Res2007;32696:doi:10.1155/2007/32696.
   PubMed Web of Science ®Google Scholar
• ZhouXOnoHFrohlichEAldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamicsAm J Nephrol20042424224915031627
   PubMed Web of Science ®Google Scholar
• MakinoHHanedaMBabazonoTPrevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetesDiabetes Care2007301577157817389334
   PubMed Web of Science ®Google Scholar